APVO: aptevotherapeutics.com Company Value to Net Income
Aptevo Therapeutics (APVO) operates within the stable North American region, where medical research remains shielded from sanctions and trade conflicts. Aptevo Therapeutics is expanding its bispecific antibody portfolio via the ADAPTIR system to drive expansion in the immuno-oncology sector. This chart captures a P/E ratio of 0.00. Revenue is generated through government contracts for the supply of Alphanate and the development of cancer therapies for specialized clinics.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_APVO_-_Aptevo-Therapeutics_-_PE-Multiple "APVO: Aptevo Business Payback Period 07/04/2022 - 11/14/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Aptevo (APVO)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Aptevo Therapeutics|APVO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital aptevotherapeutics.com|APVO - Company Debts|Debt to Book Value Ratio Aptevo Therapeutics, Inc.|APVO - Company Long-Term Debts|Short-Term Debt Aptevo Therapeutics|Quick Ratio aptevotherapeutics.com
- earnings and market multiples details:
APVO - Company Net Income|Forward Earnings Aptevo Therapeutics|APVO - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Aptevo Therapeutics|APVO - PEG Multiple|Company Value to EBITDA Aptevo Therapeutics Inc.|APVO - Operating profit before deduction of amortization|Earnings per share for the last twelve months Aptevo Therapeutics|APVO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months aptevotherapeutics.com|APVO - Net earnings per share growth this year|Expected earnings per share trend next year Aptevo Therapeutics
- sales volume and revenue indicators:
Comprehensive company analysis:Aptevo Therapeutics Inc. APVO
The P/E ratio is calculated as the ratio of market capitalization to net income, measuring the cost of one dollar of annual earnings. This multiple determines a business's actual ability to generate cash flow and identifies phases of fundamental undervaluation. For Aptevo Therapeutics (APVO), this metric reflects the efficiency of R&D investments and the retention of scientists through stock options. Analyzing the company's quarterly P/E helps assess the asset's margin of safety, while the price action of the curve captures optimal entry points.
Key competitors
P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Business Payback Period KalVista Pharma (KALV)|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Price to Earnings Ratio|Market Cap to Net Income RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Company Value to Net Income|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics, Inc - P/E Multiple|Market Cap to Net Income TLSA|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Bio|Price to Earnings Ratio Theratechnologies, Inc.|Market Cap to Earnings Avalo Therapeutics AVTX|P/E Multiple ELDN|AGEN (Agenus, Inc.) - Company Value to Net Income|Price to Earnings Ratio Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Market Cap to Earnings|ATYR: Price to Earnings Ratio|adagene.com (ADAG) - Price to Earnings Ratio|Ikena Oncology (IMA) - Price to Earnings Ratio|Price to Earnings Ratio Shattuck Labs, Inc.|Price to Earnings Ratio equilliumbio.com|Price to Earnings Ratio connectbiopharm.com (CNTB)|P/E Multiple IMUX|Business Payback Period Atara Bio|Price to Earnings Ratio InflaRx N.V. IFRX|X4 Pharmaceuticals - Price to Earnings Ratio|ACET: Price to Earnings Ratio|Company Value to Net Income CELU (celularity.com)|INMB: P/E Multiple|BRNS: Market Price to Net Income Ratio|KZR (Kezar Life Sciences, Inc.) - P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Business Payback Period|P/E Multiple AKTX|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd)|Price to Earnings Ratio Q32 Bio Inc. QTTB|GOVX - Price to Earnings Ratio|EDSA - Price to Earnings Ratio|Market Cap to Earnings iBio|CARM: P/E Multiple|Market Cap to Net Income XTLB (XTL Biopharmaceuticals, Ltd.)|Price to Earnings Ratio boltbio.com|P/E Multiple HCW Biologics|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple
